Exemplos de uso de Tumour types em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
The following tumour types were eligible.
Tumour types included were Ewing's Sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma, and rhabdomyosarcoma.
The following tumour types were not eligible.
Ipilimumab has been administered to approximately 10,000 patients in a clinical program evaluating its use with various doses and tumour types.
It can be associated with certain tumour types(paraneoplastic form of LEMS) or in the absence of these tumours non-paraneoplastic form of LEMS.
The optimum regimen for safe administration of gemcitabine with therapeutic doses of radiation has not yet been determined in all tumour types.
This is consistent with population pharmacokinetic data derived from clinical trials in various tumour types see“Population pharmacokinetic analysis in special populations” below.
In post-marketing surveillance, serious and fatal carotid artery haemorrhages were seen more frequently in patients with anaplastic thyroid carcinoma(ATC)than in DTC or other tumour types.
Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including cases of central nervous system(CNS) bleeding in patients with CNS metastases see section 4.4.
The safety and tolerability of nivolumab were investigated in a phase 1,open-label dose-escalation study in various tumour types, including malignant melanoma.
Based on population pharmacokinetic data derived from clinical trials in various tumour types, an average decrease of 26% in AUCτ, ss was observed when food was consumed within 3 hours before or 1 hour after taking GIOTRIF.
In long-term carcinogenicity studies at doses of ranolazine up to 50 mg/kg/day (150 mg/m2/day) in mice and 150 mg/kg/day (900 mg/m2/day)in rats, no relevant increases in the incidence of any tumour types were seen.
However the heterogenicity of the data and the other measured variables(such as age,staging, tumour types, site) makes it difficult to recommend more than just that the NLR is a useful indicator.
In two large, open-label studies, 2697 cancer patients receiving non-platinum chemotherapy were included, 1895 with solid tumours(683 breast, 260 lung, 174 gynaecological, 300 gastrointestinal, and478 other tumour types) and 802 with haematological malignancies.
Patients receiving the aprepitant regimen were receiving chemotherapy for a variety of tumour types including 52% with breast cancer, 21% with gastrointestinal cancers including colorectal cancer, 13% with lung cancer and 6% with gynaecological cancers.
In two large, open-label studies, 2697 cancer patients receiving non-platinum chemotherapy were included, 1895 with solid tumours(683 breast, 260 lung, 174 gynaecological, 300 gastro-intestinal, and478 other tumour types) and 802 with haematological malignancies.
Tumour-associated haemorrhage was also seen rarely in other tumour types and locations, including a case of central nervous system(CNS) bleeding in a patient with hepatoma with occult CNS metastases(see section 4.3) and another patient who developed continuous oozing of blood from a thigh sarcoma with necrosis.
A post-hoc analysis in study 2(patients with other solid tumours or multiple myeloma) examined overall survival for the 3 tumour types used for stratification non-small cell lung cancer, multiple myeloma, and other.
Cancer patients receiving non-platinum chemotherapy were included in three placebo-controlled studies, 389 patients with haematological malignancies(221 multiple myeloma, 144 non-Hodgkin's lymphoma, and 24 other haematological malignancies) and 332 with solid tumours 172 breast, 64 gynaecological, 23 lung, 22 prostate, 21 gastrointestinal, and30 other tumour types.
The following immune-related adverse reactions were reported in less than 1% of patients treated with nivolumab in clinical trials across doses and tumour types: pancreatitis, uveitis, demyelination, autoimmune neuropathy(including facial and abducens nerve paresis), Guillain-Barré syndrome, hypopituitarism, and myasthenic syndrome.
Cancer patients receiving non-platinum chemotherapy were included in three placebo-controlled studies, 389 patients with haematological malignancies(221 multiple myeloma, 144 non-Hodgkin's lymphoma, and 24 other haematological malignancies) and 332 with solid tumours 172 breast, 64 gynaecological, 23 lung, 22 prostate, 21 gastro-intestinal, and30 other tumour types.
In an exploratory retrospective analysis of data from 13 completed randomised trials in patients with various tumour types, 3 patients out of 91(3.3%) with brain metastases experienced CNS bleeding(all Grade 4) when treated with bevacizumab, compared to 1 case(Grade 5) out of 96 patients(1%) that were not exposed to bevacizumab.
There was no significant increase in any other tumour type in either male or female mice or rats.
A population PK analysis suggested no difference in CL of nivolumab based on age, gender,race, tumour type, tumour size, and hepatic impairment.
Consideration should be given to the severity of the hypercalcaemia as well as the tumour type.
It is a drug used to treat various tumours types, and also to prevent rejection in organ transplantation and autoimmune diseases such as rheumatoid arthritis and lupus erythematosus.
Background incidence of this tumour type in rats as well as humans is very low and the mechanism causing these tumours in the rat studies(including its relation to ataluren treatment) is unknown.
Results suggest that age,gender, tumour type, race, hepatic function, renal function, chemotherapeutic agents, and EGFR expression in tumour cells had no apparent impact on the pharmacokinetics of panitumumab.
The benefit of aprepitant combination therapy in the full study population was mainly driven by the results observed in patients with poor control with the standard regimensuch as in women, even though the results were numerically better regardless of age, tumour type or gender.
The median survival by histology tumour type was 16.2 months[95% CI: 14.1, 19.5] for subjects with leiomyosarcomas and liposarcomas and 8.4 months[95% CI: 7.1, 10.7] for subjects with other types of sarcomas.